Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial - Goebeler, M; Bata-Csorgo, Z; De Simone, C (Br J Dermatol, 2022)
et al.